Logo image of LUCD

LUCID DIAGNOSTICS INC (LUCD) Stock Fundamental Analysis

USA - NASDAQ:LUCD - US54948X1090 - Common Stock

1.25 USD
+0.07 (+5.93%)
Last: 10/20/2025, 8:00:01 PM
1.266 USD
+0.02 (+1.28%)
Pre-Market: 10/21/2025, 8:00:01 AM
Fundamental Rating

2

Overall LUCD gets a fundamental rating of 2 out of 10. We evaluated LUCD against 190 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of LUCD have multiple concerns. LUCD is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LUCD had negative earnings in the past year.
In the past year LUCD has reported a negative cash flow from operations.
In the past 5 years LUCD always reported negative net income.
LUCD had a negative operating cash flow in each of the past 5 years.
LUCD Yearly Net Income VS EBIT VS OCF VS FCFLUCD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

LUCD has a Return On Assets of -175.38%. This is amonst the worse of the industry: LUCD underperforms 91.05% of its industry peers.
LUCD's Return On Equity of -862.60% is on the low side compared to the rest of the industry. LUCD is outperformed by 86.84% of its industry peers.
Industry RankSector Rank
ROA -175.38%
ROE -862.6%
ROIC N/A
ROA(3y)-179.51%
ROA(5y)-192.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LUCD Yearly ROA, ROE, ROICLUCD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

1.3 Margins

LUCD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LUCD Yearly Profit, Operating, Gross MarginsLUCD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -5K -10K

More info and screens

1

2. Health

2.1 Basic Checks

LUCD does not have a ROIC to compare to the WACC, probably because it is not profitable.
LUCD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, LUCD has more shares outstanding
Compared to 1 year ago, LUCD has an improved debt to assets ratio.
LUCD Yearly Shares OutstandingLUCD Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
LUCD Yearly Total Debt VS Total AssetsLUCD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -9.47, we must say that LUCD is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of LUCD (-9.47) is worse than 79.47% of its industry peers.
A Debt/Equity ratio of 3.22 is on the high side and indicates that LUCD has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 3.22, LUCD is doing worse than 85.79% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 3.22
Debt/FCF N/A
Altman-Z -9.47
ROIC/WACCN/A
WACC8.15%
LUCD Yearly LT Debt VS Equity VS FCFLUCD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 1.15 indicates that LUCD should not have too much problems paying its short term obligations.
The Current ratio of LUCD (1.15) is worse than 84.21% of its industry peers.
LUCD has a Quick Ratio of 1.13. This is a normal value and indicates that LUCD is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of LUCD (1.13) is worse than 71.05% of its industry peers.
Industry RankSector Rank
Current Ratio 1.15
Quick Ratio 1.13
LUCD Yearly Current Assets VS Current LiabilitesLUCD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

6

3. Growth

3.1 Past

LUCD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.57%, which is quite good.
The Revenue has grown by 14.83% in the past year. This is quite good.
LUCD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 105.61% yearly.
EPS 1Y (TTM)15.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.22%
Revenue 1Y (TTM)14.83%
Revenue growth 3Y105.61%
Revenue growth 5YN/A
Sales Q2Q%19.16%

3.2 Future

Based on estimates for the next years, LUCD will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.84% on average per year.
LUCD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 75.22% yearly.
EPS Next Y31.82%
EPS Next 2Y28.34%
EPS Next 3Y19.93%
EPS Next 5Y11.84%
Revenue Next Year6.34%
Revenue Next 2Y67.51%
Revenue Next 3Y82.12%
Revenue Next 5Y75.22%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
LUCD Yearly Revenue VS EstimatesLUCD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
LUCD Yearly EPS VS EstimatesLUCD Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LUCD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LUCD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LUCD Price Earnings VS Forward Price EarningsLUCD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LUCD Per share dataLUCD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

LUCD's earnings are expected to grow with 19.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.34%
EPS Next 3Y19.93%

More info and screens

0

5. Dividend

5.1 Amount

LUCD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LUCID DIAGNOSTICS INC

NASDAQ:LUCD (10/20/2025, 8:00:01 PM)

Premarket: 1.266 +0.02 (+1.28%)

1.25

+0.07 (+5.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners14.92%
Inst Owner Change0.68%
Ins Owners4.5%
Ins Owner Change2.14%
Market Cap171.54M
Analysts83.33
Price Target3.78 (202.4%)
Short Float %8.56%
Short Ratio5.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-93.54%
Min EPS beat(2)-222.25%
Max EPS beat(2)35.18%
EPS beat(4)2
Avg EPS beat(4)-47.84%
Min EPS beat(4)-222.25%
Max EPS beat(4)35.18%
EPS beat(8)3
Avg EPS beat(8)-32.2%
EPS beat(12)6
Avg EPS beat(12)-16.35%
EPS beat(16)6
Avg EPS beat(16)-19.88%
Revenue beat(2)0
Avg Revenue beat(2)-18.46%
Min Revenue beat(2)-36.75%
Max Revenue beat(2)-0.17%
Revenue beat(4)1
Avg Revenue beat(4)-13.41%
Min Revenue beat(4)-36.75%
Max Revenue beat(4)0.77%
Revenue beat(8)1
Avg Revenue beat(8)-10.9%
Revenue beat(12)2
Avg Revenue beat(12)-17.53%
Revenue beat(16)3
Avg Revenue beat(16)-17.5%
PT rev (1m)0%
PT rev (3m)-2.2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.77%
EPS NY rev (1m)3.08%
EPS NY rev (3m)7.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-22.66%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-23.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 39.34
P/FCF N/A
P/OCF N/A
P/B 21.82
P/tB 23.38
EV/EBITDA N/A
EPS(TTM)-1.03
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS0.03
BVpS0.06
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -175.38%
ROE -862.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-179.51%
ROA(5y)-192.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 3.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 82.61%
Cap/Sales 16.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.15
Quick Ratio 1.13
Altman-Z -9.47
F-Score4
WACC8.15%
ROIC/WACCN/A
Cap/Depr(3y)37.04%
Cap/Depr(5y)N/A
Cap/Sales(3y)87.81%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.22%
EPS Next Y31.82%
EPS Next 2Y28.34%
EPS Next 3Y19.93%
EPS Next 5Y11.84%
Revenue 1Y (TTM)14.83%
Revenue growth 3Y105.61%
Revenue growth 5YN/A
Sales Q2Q%19.16%
Revenue Next Year6.34%
Revenue Next 2Y67.51%
Revenue Next 3Y82.12%
Revenue Next 5Y75.22%
EBIT growth 1Y-7.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.07%
EBIT Next 3Y9.33%
EBIT Next 5Y6.72%
FCF growth 1Y-73.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-74.54%
OCF growth 3YN/A
OCF growth 5YN/A